Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
– Results Indicate that FNAIT Risk is More Prevalent Than Previously Estimated –
“With our Phase 2 trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT on track to initiate in the fourth quarter of 2024, we continue our efforts to raise awareness of FNAIT and broaden the understanding of the population at risk for this potentially devastating disease,” said
The ASHG abstract #7041T, which can be found here, details the high-level findings of the epidemiological analysis. In this analysis, women at higher risk for alloimmunization and FNAIT were defined as those having an HPA-1a negative and HLA-DRB3*01:01 positive genotype. Allele frequencies were obtained from gnomAD v4 for HPA-1a and the
Proportions of women at risk of alloimmunizing were highest in Caucasian populations, with the highest proportions in the Ashkenazi Jewish population (2.36% and 0.65% of women at risk and at higher risk, respectively), followed by non-Finnish Europeans (2.34% and 0.64%), Middle Eastern (2.25% and 0.62%), Amish (2.25% and 0.62%), White Hispanic (2.25% and 0.59%) and Finnish (2.03% and 0.56%). Additionally, women in some non-Caucasian population groups were also found to be at risk including the Caribbean Hispanic population (1.48% and 0.33%), followed by African /
Taken together, these data indicate that the proportion of pregnant women at higher risk for FNAIT annually has been significantly underestimated. For example, in key geographies of
This analysis was conducted by
About FNAIT
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. FNAIT can arise during pregnancy due to an immune incompatibility between an expectant mother and her fetus in a specific platelet antigen called human platelet antigen 1, or HPA-1.
There are two predominant forms of HPA-1, known as HPA-1a and HPA-1b, which are expressed on the surface of platelets. Individuals who are homozygous for HPA-1b, meaning that they have two copies of the HPA-1b allele and no copies of the HPA-1a allele, are also known as HPA-1a negative. Upon exposure to the HPA-1a antigen, these individuals can develop antibodies to that antigen in a process known as alloimmunization. In HPA-1a-negative expectant mothers bearing a HPA-1a-positive fetus, alloimmunization can occur upon mixing of fetal blood with maternal blood. When alloimmunization occurs in an expectant mother, the anti-HPA-1a antibodies that develop in the mother can cross the placenta and destroy platelets in the fetus. The destruction of platelets in the fetus can result in severely low platelet counts, or thrombocytopenia, and potentially lead to devastating consequences including miscarriage, stillbirth, death of the newborn, or severe lifelong neurological disability in those babies who survive. There is currently no approved therapy for the prevention or prenatal treatment of FNAIT.
About
Forward-Looking Statements
This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the diversity of ancestries that carry the genetic markers for FNAIT, the increase in the number of pregnancies estimated to be at high risk of FNAIT each year based on the epidemiological analysis and our estimates of the number of pregnancies at higher risk of FNAIT, our ability to identify the number of pregnant women at higher risk of FNAIT based on the results of the analysis, our ability to ensure routine prenatal screening, the timing of initiation of the Phase 2 dose confirmation study for RLYB212, our expectations regarding the usefulness of data from our clinical studies, and the timing of publications relating to FNAIT and RLYB212. The forward-looking statements in this press release are only predictions and are based largely on management’s current expectations and projections about future events and financial trends that management believes may affect Rallybio’s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 2 clinical trial for RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920956554/en/
Investor Contacts
(475) 47-RALLY (Ext. 282)
investors@rallybio.com
Precision AQ
(212) 698-8691
kevin.lui@precisionaq.com
Media Contact
Mission North
(760) 579-2134
rallybio@missionnorth.com
Source:
